![GRAPHIC](https://content.edgar-online.com/edgar_conv_img/2023/02/28/0001104659-23-026551_tm237969d1_6kp1img-130.jpg)
| 2022 2021 (*) 2020 (*) 2022 2021 (*) 2020 (*) 2022 2021 (*) 2020 (*) 2022 2021 (*) 2020 (*) 2022 2021 (*) 2020 (*) 2022 2021 (*) 2020 (*)
Revenues from external customers 5,005,382 3,814,983 4,242,502 671,292 779,108 775,889 146,076 115,811 133,221 250,165 266,461 222,521 (8,94 (43,245) 8) (34,095) -25,386 6,063,967 4,933,118 5,340,038
Total operating income 3,814,983 5,005,382 4,242,502 671,292 779,108 775,889 146,076 115,811 133,221 250,165 266,461 222,521 (8,948) (43,245) (34,095) (25,386) 6,063,967 4,933,118 5,340,038
Profit/(Loss) for the segment 791,339 681,925 967,415 129,968 152,948 215,793 114,397 39,901 36,142 (46,809) (83,482) (43,960) 35,419 (10,896) 4,428 (305) 1,024,314 780,396 1,179,818
Unallocated expenses (185,332) (218,634) (183,686)
Operating profit/(loss) 805,680 595,064 996,132
Finance result (277,799) (442,941) (177,669)
Share of profit/(loss) of equity-accounted investee -- -- -- -- -- -- -- -- -- (1,482) 33,188 60,166 -- -- -- -- 33,188 (1,482) 60,166
Income tax expense (85,126) (90,111) (169,639)
Profit for the year after tax 271,146 265,327 708,990
Segment assets 13,187,651 9,467,378 7,975,667 3,681,632 3,513,991 3,371,125 341,876 47,446 251,551 766,139 827,371 641,341 (6,997) (39,963) (26,773) 17,970,301 13,816,223 12,212,911
Equity-accounted investments 41,162 31,847 -- -- -- -- -- 53,264 46,782 1,914,015 1,914,665 1,822,238 -- -- -- 1,955,177 1,999,776 1,869,020
Unallocated assets -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- 1,608,499 3,417,836 1,192,845
Total assets 21,533,977 19,233,835 15,274,776
Segment liabilities 2,317,191 1,521,634 1,222,664 425,693 397,869 372,461 43,264 27,596 120,787 222,565 199,095 153,513 -- -- -- 3,008,713 2,146,194 1,869,425
Unallocated liabilities -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- 10,067,720 9,770,543 6,685,296
Total liabilities 13,076,433 11,916,737 8,554,721
Other information:
Allocated amortisation and depreciation 294,156 228,114 201,087 64,682 88,557 63,053 5,759 2,948 21,846 20,367 19,043 15,263 -- -- -- 338,662 384,964 301,249
Unallocated amortisation and depreciation -- -- -- -- -- -- -- -- -- -- -- -- -- -- -- 21,105 22,900 20,284
Allocated expenses that do not require cash payments 26,051 (71,964) 38,955 13,639 4,446 (21,335) 120 73 3 (206) 3,349 (2,448) -- -- -- 33,919 (58,411) 15,175
Unallocated expenses that do not require cash
payments
-- -- -- -- -- -- -- -- -- -- -- -- -- -- -- 4,991 (10,770) 4,924
Allocated additions for the year of property, plant &
equipment, intangible assets and rights of use 402,672 349,890 289,062 49,890 19,991 34,516 98 13,836 10,915 30,192 28,597 12,698 -- -- -- 482,852 412,314 347,191
Unallocated additions for the year of property, plant
& equipment, intangible assets and rights of use
-- -- -- -- -- -- -- -- -- -- -- -- -- -- -- 59,866 55,380 107,178
* As a consequence of the review of transactions and balances allocations by segments, the comparative figures for the fiscal year 2021 and 2020 have been adjusted accordingly.
This appendix forms an integral part of note 5 to the consolidated annual accounts.
Consolidated
APPENDIX II
GRIFOLS, S.A. AND SUBSIDIARIES
Operating Segments for the years ended 31 December 2022, 2021 and 2020
(Expressed in thousands of Euros)
(Free translation from the original in Spanish. In the event of discrepancy, the Spanish-language version prevails)
Biopharma Diagnostic Bio Supplies Others Intersegments
1 of 2 |